5-Chlor-2-ethylaminopyridin | 33360-09-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-Chlor-2-ethylaminopyridin
• 英文别名: (5-chloro-pyridin-2-yl)-ethyl-amine；5-chloro-N-ethylpyridin-2-amine
• CAS: 33360-09-7
• 化学式: C₇H₉ClN₂
• 分子量: 156.615
• InChiKey: SVEJPHCGJCVNEJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tert-butyl (6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]thiazol-2-yl)carbamate 、 5-Chlor-2-ethylaminopyridin 在 Pd-118 作用下， 以 水 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Discovery of potent, selective small molecule inhibitors of α-subtype of type III phosphatidylinositol-4-kinase (PI4KIIIα)

  摘要：

  The discovery and optimisation of novel, potent and selective small molecule inhibitors of the alpha-isoform of type III phosphatidylinositol-4-kinase (PI4K alpha) are described. Lead compounds show cellular activity consistent with their PI4K alpha potency inhibiting the accumulation of IP1 after PDGF stimulation and reducing cellular PIP, PIP2 and PIP3 levels. Hence, these compounds are useful in vitro tools to delineate the complex biological pathways involved in signalling through PI4Ka. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.05.093

文献信息

• [EN] MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE<br/>[FR] MODULATEURS D'INDOLAMINE 2,3-DIOXYGÉNASE
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018116107A1

  公开（公告）日：2018-06-28

  Provided are IDO inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases such as chronic viral infection, chronic bacterial infections, cancer, sepsis or a neurological disorder.

  提供了式（I）的IDO抑制剂化合物及其药学上可接受的盐，它们的药物组合物，它们的制备方法，以及它们在预防和/或治疗慢性病毒感染、慢性细菌感染、癌症、败血症或神经系统疾病等疾病中的使用方法。
• PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS
  申请人：Fink Brian E.

  公开号：US20090048244A1

  公开（公告）日：2009-02-19

  The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供公式I化合物及其药学上可接受的盐。公式I化合物抑制生长因子受体的酪氨酸激酶活性，如HER1、HER2和HER4，因此使它们有用作抗增殖剂。公式I化合物也适用于治疗与通过生长因子受体进行信号转导途径相关的其他疾病。
• 17 Beta-Acetamide-4-Azasteroids As Androgen Receptor Modulators
  申请人：Wang Jiabing

  公开号：US20080125399A1

  公开（公告）日：2008-05-29

  Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

  结构式（I）的化合物以组织选择性的方式调节雄激素受体（AR）。这些化合物有助于增强肌肉张力减弱和治疗由雄激素缺乏引起或可以通过雄激素治疗改善的疾病，包括骨质疏松症、骨质疏松、糖皮质激素诱导的骨质疏松症、牙周病、骨折、骨重建手术后的骨损伤、肌肉萎缩、衰弱、老化皮肤、男性性腺功能减退、女性绝经后症状、动脉硬化、高胆固醇血症、高脂血症、肥胖症、再生障碍性贫血和其他造血系统疾病、炎性关节炎和关节修复、艾滋病消耗综合征、前列腺癌、良性前列腺增生症（BPH）、癌症消耗综合征、阿尔茨海默病、肌营养不良、认知能力下降、性功能障碍、睡眠呼吸暂停、抑郁症、早发性卵巢衰竭和自身免疫性疾病，可单独使用或与其他活性剂联合使用。
• IMIDAZO[1,2-a]PYRIDINE COMPOUNDS
  申请人：Fang Qun Kevin

  公开号：US20110166146A1

  公开（公告）日：2011-07-07

  Imidazo[1,2-a]pyridines are disclosed. Compounds of the invention are useful therapeutic agents and their inclusion in pharmaceutical formulations and use in methods of treatment are disclosed.

  本发明揭示了咪唑并[1,2-a]吡啶类化合物。该发明的化合物是有用的治疗剂，揭示了它们在制药配方中的包含以及在治疗方法中的使用。
• INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE
  申请人：Centaurus Therapeutics

  公开号：US20190328720A1

  公开（公告）日：2019-10-31

  Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.